FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年9月30日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02196 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 ...

格隆汇9月30日丨复星医药(02196.HK)发布公告，吴以芳因个人工作变动辞任非执行董事，自2025年9月 30日起生效；及建议委任刘毅为第十届董事会执行董事。 ...

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for its injectable HLX43, a targeted antibody-drug conjugate (ADC) developed in collaboration with a new DNA topoisomerase I inhibitor [1] Group 1 - The HLX43 is a conjugate of a newly licensed small molecule toxin-peptide chain and an independently developed PD-L1 targeting antibody [1]

Core Viewpoint - Shanghai Fosun Pharmaceutical's subsidiary, Fuhong Hanlin, has received approval from the National Medical Products Administration to conduct clinical trials for HLX43 in combination with HLX07 for the treatment of advanced/metastatic solid tumors [1] Group 1: Clinical Trials and Drug Development - The clinical trials will be conducted domestically, focusing on Phase Ib/II studies [1] - HLX43 is a targeted PD-L1 antibody-drug conjugate, while HLX07 is an innovative biopharmaceutical targeting the EGFR [1] - As of September 30, 2025, multiple clinical studies for HLX43 are being conducted globally, and several Phase II clinical studies for HLX07 are underway in China [1] Group 2: Financial Investment and Market Context - Cumulative research and development investment for this treatment regimen has reached approximately 150,000 yuan as of August [1] - There are currently no similar combination therapies approved for market globally [1]

Group 1 - The company Fosun Pharma (600196)(02196) announced the resignation of Mr. Wu Yifang as a non-executive director, effective from September 30, 2025 [1] - The company proposed the appointment of Mr. Liu Yi as an executive director of the tenth board of directors [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 董事名單及彼等之角色及職責 上海復星醫藥（ 集團 ）股份有限公司董事會（「董事會」）目前包括11名董事。彼等之名稱、角 色及職責載列如下： 執行董事： 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 陳玉卿先生 （ 董事長） 關曉暉女士 （ 聯席董事長） 文德鏞先生 （ 副董事長） 王可心先生 非執行董事： 陳啟宇先生 潘東輝先生 獨立非執行董事： 余梓山先生 王全弟先生 Chen Penghui先生 楊玉成先生 職工董事： 中國，上海 2025年9月30日 * 僅供識別 嚴佳女士 – 1 – 董事會設有五個專門委員會。各董事會成員於該等委員會中所擔任之職位載於下表： | | | | | 薪酬與 | 環境、社會 | | -- ...

Group 1 - The chemical pharmaceutical sector increased by 1.63% on September 30, with Mengke Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3882.78, up 0.52%, while the Shenzhen Component Index closed at 13526.51, up 0.35% [1] - Notable gainers in the chemical pharmaceutical sector included Mengke Pharmaceutical, which rose by 8.45% to a closing price of 9.11, and Yong'an Pharmaceutical, which increased by 6.92% to 18.08 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 256 million yuan from main funds, while retail investors experienced a net outflow of 320 million yuan [2] - Key stocks with significant main fund inflows included Heng Rui Pharmaceutical with 37.4 million yuan and Yong'an Pharmaceutical with 134 million yuan [3] - Conversely, stocks like ST Suwu and ST Fuhua experienced declines of 5.00% and 4.97%, respectively, indicating a mixed performance within the sector [2]

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） (1)非執行董事辭任 及 董事會宣佈以下非執行董事的辭任及建議委任執行董事： (1) 吳以芳先生因個人工作變動辭任非執行董事，自2025年9月30日起生效；及 (2) 建議委任劉毅先生為第十屆董事會執行董事。 通函 本公司將於適當時候向股東寄發一份載有（ 其中包括 ）有關建議委任劉毅先生為執行董事 之進一步詳情連同股東會通告之通函。 非執行董事辭任 於2025 年9 月30 日，上 海復星醫 藥（ 集團 ）股份 有限公司（「本公司」，連 同其附屬 公司，「本 集團」）董事（「董事」）會（「董事會」）收到吳以芳先生（「吳先生」）之辭職函，吳先生因個人工 作變動，向董事會辭任本公司 ...

Core Viewpoint - Fosun Pharma is facing significant cash flow pressure, prompting the company to dispose of assets to improve liquidity and support its transition to innovative drug development [2][3][12]. Group 1: Asset Disposal - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Clone for a transaction price not exceeding 1.256 billion yuan [2]. - This transaction is part of a broader strategy, with the company having signed asset disposal agreements totaling over 2 billion yuan by mid-2025 [2]. - The asset transfer involves setting up a fund, with Fosun Pharma contributing 54.6 million yuan as a limited partner [2]. Group 2: Financial Pressure - As of mid-2025, Fosun Pharma's short-term borrowings reached 17.862 billion yuan, with total short-term debt amounting to 22.646 billion yuan, significantly exceeding cash reserves of 12.959 billion yuan [3][5]. - The company's financial expenses for the first half of 2025 amounted to 640 million yuan, the highest since its listing, consuming two-thirds of its net profit excluding non-recurring items [3][5]. Group 3: Debt Structure - Fosun Pharma's debt structure shows a high reliance on short-term debt, with 61% of its interest-bearing liabilities being short-term [5]. - The company's debt-to-asset ratio stands at 49.24%, higher than the average of 40% for A-share pharmaceutical companies [6]. - The cash coverage ratio is approximately 0.12, indicating a significant liquidity risk [7]. Group 4: Performance Metrics - For the first half of 2025, Fosun Pharma reported revenue of 19.514 billion yuan, a year-on-year decline of 4.63%, while net profit attributable to shareholders was 1.702 billion yuan, up 38.96% [9]. - The profit increase is largely attributed to asset disposal gains of 9.491 billion yuan, nearly doubling from the previous year [11]. - The company's core operating profit, reflected in the net profit excluding non-recurring items, fell by 23.39% to 961 million yuan [12]. Group 5: Innovation and Market Position - Fosun Pharma's innovative drug revenue growth is lagging behind industry leaders, with its PD-1 product "Hanshu" showing a 15% increase in revenue, compared to 28% for competitors [12][13]. - The proportion of revenue from innovative drugs is approximately 25%, lower than the 35% seen in leading companies like Heng Rui [13]. - The reliance on non-recurring investment income raises concerns about the sustainability of profit growth, as the company has not yet achieved scale effects in its high-margin innovative drugs [13].

Core Points - The company will hold its first extraordinary general meeting of shareholders in 2025 on October 23, 2025 [2][3] - The meeting will utilize the Shanghai Stock Exchange's online voting system for A-share shareholders [2][4] - The meeting will take place at Shanghai Tianxi Jiafu Putike Hotel, starting at 13:30 [3] Meeting Details - The meeting is convened by the board of directors [3] - A-share shareholders can vote both on-site and online [3] - The online voting will be available during specific trading hours on the day of the meeting [4] Voting Procedures - A-share shareholders must follow specific procedures for voting through margin trading and other accounts [5] - There are no applicable provisions for public solicitation of shareholder voting rights [6] - The voting results will be based on the first vote cast if multiple votes are submitted [11] Agenda Items - The meeting will review several proposals that have been previously disclosed [7] - Special resolutions will include proposals 1 to 5, with separate counting for small investors [8] - Certain shareholders are required to abstain from voting on specific proposals due to conflicts of interest [8][9] Attendance Information - A-share shareholders must register to attend the meeting, either online or on-site [12][15] - H-share shareholders have separate registration procedures detailed on the Hong Kong Stock Exchange website [14][19] - All expenses related to attending the meeting are to be borne by the shareholders themselves [21] Contact Information - Shareholders can contact the company's board secretary office for further inquiries [22][25]